A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

About the trial

Sponsor

AbbVie

Tested

Elsubrutinib (drug), Placebo for Elsubrutinib (drug), Upadacitinib (drug), Placebo for Upadacitinib (drug)

Dates

Started 2020-07-27; completion 2024-01-03

Results posted

Yes

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib given alone or as the ABBV-599 combination (elsubrutinib/upadacitinib) works within the body, in participants who completed study M19-130. This study will assess the change in disease symptoms. ABBV-599 is an investigational drug being developed for the treatment of Systemic Lupus Erythematosus (SLE). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants into 1 of 4 groups called …

From ClinicalTrials.gov, last updated 2025-01-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $22,422 in research payments for this study in 2025 (3 payments).

Products named: Rinvoq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.